NEW YORK (GenomeWeb) – Chinese personalized oncology firm Burning Rock Biotech announced last week that it has closed a CNY150 million ($23.4 million) Series A+ financing round led by Jifeng Capital, Sequioa Capital, and Legend Star.

The firm said in a statement that it would use the proceeds to fund research and development. Burning Rock offers next-generation sequencing-based cancer diagnostics and personalized treatment plants based on genetic testing.

Burning Rock received CNY62 million in Series A financing in 2014 from Northern Light Venture Capital and Legend Star.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.